Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
World Journal of Otorhinolaryngology - Head and Neck Surgery|August 14, 2018
Taste acceptability of thickening agentsChristina M Yver, William P Kennedy, Natasha Mirza
Journal of Molecular Biology|May 22, 2007
Mechanism for de novo RNA synthesis and initiating nucleotide specificity by t7 RNA polymeraseWilliam P Kennedy, Jamila R Momand, Y Whitney Yin
Developmental Dynamics : an Official Publication of the American Association of Anatomists|May 10, 2014
Transcriptionally regulated cell adhesion network dictates distal tip cell directionalityMing-Ching Wong, William P Kennedy, Jean E Schwarzbauer
JAMA Otolaryngology-- Head & Neck Surgery|January 1, 2016
A Critical Period in Postnatal Neuroplasticity of Olfaction: A Pediatric Tracheostomy ModelWilliam P Kennedy, Cameron P Lewis, Joanne Stow, et al.
The Laryngoscope|October 1, 2015
Trauma-induced schwannoma of the recurrent laryngeal nerve after thyroidectomyWilliam P Kennedy, Robert M Brody, Virginia A LiVolsi, et al.
American Journal of Cancer Research|August 27, 2013
Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinomaChristina A von Roemeling, Laura A Marlow, William P Kennedy, et al.
Annals of the Rheumatic Diseases|June 4, 2015
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, et al.
Gynecologic Oncology|November 26, 2011
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancerPrakash Vishnu, Gerardo Colon-Otero, Gregory T Kennedy, et al.
Arthritis and Rheumatism|July 27, 2012
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation studyJacqueline M McBride, Jenny Jiang, Alexander R Abbas, et al.
Arthritis Research & Therapy|November 1, 2014
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)William P Kennedy, J Abraham Simon, Carolyn Offutt, et al.
Pageof 2